Ceulemans Michael, Cuppers B, de Vries L, Allegaert K, Duvekot J J, van Puijenbroek E P
Lareb, Teratologie Informatie Service, 's-Hertogenbosch.
KU Leuven, Dept. Farmaceutische en Farmacologische Wetenschappen, Onderzoeksgroep Klinische farmacologie en farmacotherapie, Leuven.
Ned Tijdschr Geneeskd. 2021 Feb 9;164:D5036.
SARS-CoV-2 has rapidly spread worldwide since December 2019. Obviously, pregnant and lactating women will also be infected with SARS-CoV-2. Pregnant women, however, are a risk population for developing severe respiratory infections. Currently, the knowledge on potential risks and consequences of COVID-19 during pregnancy and lactation is limited. Available data show that pregnant women suffer from similar symptoms compared to non-pregnant patients. There is no evidence as yet that COVID-19 has a more serious course during pregnancy. Although pregnant women might suffer from a wide variety of symptoms, most of them are asymptomatic. Maternal SARS-CoV-2 infection might lead to adverse neonatal outcomes, such as prematurity or respiratory symptoms. There is currently no conclusive evidence of absence of intrauterine transmission of the virus; the virus has not been detected in breastmilk in most studies, although passage into breastmilk cannot be completely excluded.
自2019年12月以来，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）已在全球迅速传播。显然，孕妇和哺乳期妇女也会感染SARS-CoV-2。然而，孕妇是发生严重呼吸道感染的高危人群。目前，关于2019冠状病毒病（COVID-19）在妊娠和哺乳期的潜在风险及后果的知识有限。现有数据表明，与非孕妇患者相比，孕妇出现的症状相似。尚无证据表明COVID-19在孕期的病程更严重。虽然孕妇可能会出现各种各样的症状，但大多数人没有症状。孕产妇感染SARS-CoV-2可能会导致不良的新生儿结局，如早产或呼吸道症状。目前尚无确凿证据表明不存在病毒的宫内传播；在大多数研究中，尚未在母乳中检测到该病毒，不过不能完全排除病毒进入母乳的可能性。
